P&T COMMITTEE MEETING

Agenda January 08, 2019
1:00 p.m. – 5:00 p.m.

303 E. 17th Ave, 11th Floor Conference Rooms (11ABC), Denver, CO 80203

• Committee Member Introductions: openings/new appointments
• Vote on New Chair/Vice Chair

Unfinished Business and General Orders
• Approval of minutes from October 02, 2018 P&T meeting
• Update on Anti-Depressants, Newer Generation
  o Other – Including Monoamine Oxidase Inhibitors (MAOIs)
  o Tricyclics (TCAs)
• Update on Anti-Emetics
• Update on Antihyperuricemics
• Update on Antipsoriatics (Oral and Topical)
• Update on Antiviral Agents (Oral)
• Update on Epinephrine Auto-Injector Products
• Update on Fluoroquinolones
• Update on Hepatitis C Virus Treatments
  o Direct-Acting Antivirals
  o Ribavirin-Containing Agents
• Update on NSAIDs (Oral and Non-Oral)
• Update on Proton Pump Inhibitors
• Update on Pulmonary Arterial Hypertension (PAH) Agents
  o Endothelial Antagonists
  o Phosphodiesterase Inhibitors
  o Prostanoids
• Update on Targeted Immune Modulators (TIMs)
• Update on Ulcerative Colitis Agents (Oral and Non-Oral)
• Update on Mass review drug classes:
  o Anti-Herpetics – Oral and Topical
  o H. Pylori Treatments
  o Anti-Platelets
  o Pancreatic Enzymes
  o PAH Agents: Guanylate Cyclase Stimulators
  o Triptans

New Business

1. P&T Policies and Procedure Update

2. Updates from the Prior Authorization Call Center
Drug Classes Up for Review:

- Review of Atypical Antipsychotics (Oral)
- Review of Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- Review of Growth Hormones
- Review of Insulins
- Review of Intranasal Rhinitis Agents
- Review of Lipotropics and Bile Salts
- Review of Multiple Sclerosis Agents
- Review of Neurocognitive Disorder Agents
- Review of Anti-Parkinson Agents
- Review of Ophthalmic Glaucoma Agents
- Review of Topical Steroids
- Mass review drug classes*:
  - Leukotriene Modifiers
  - Statins & Statin Combinations
  - Sedative Hypnotics (Non-Benzodiazepine and Benzodiazepine)
  - Ophthalmic Allergy Agents

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share and FDA updates
- Committee Discussion and Recommendations for each Class

*Mass review drug classes will only include:

- Overview for each Drug Class, including market share and FDA updates

Upcoming Meeting Date: Tuesday, April 2, 2019; 1:00 p.m. – 5:00 p.m.

Presentations:

Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical information that will be presented for P&T Committee dissemination.

Please contact Brittany Schock, PDL Pharmacist, at 303-866-6371 or by email at brittany.schock@state.co.us to give advance notice to present at the meeting. Written public comments can be submitted to Jessica Czechowski, Clinical Account Manager jlczechowski@magellanhealth.com (carbon copy Brittany Schock) and will be distributed to all present P&T Committee Members. Please provide public comments by December 28, 2018 for dissemination to the P&T Committee.